Loading...
•
Jun 30, 2023
Editas Q2 2023 Earnings Report
Editas Medicine's EDIT-301 program advanced towards a BLA filing, and the company strengthened its executive team.
Key Takeaways
Editas Medicine reported a net loss of $40.3 million, or $0.56 per share, for the second quarter of 2023. The company's cash, cash equivalents, and marketable securities were $480.0 million as of June 30, 2023, which is expected to fund operating expenses and capital expenditures into the third quarter of 2025. The company is on track to dose 20 total patients in the EDIT-301 RUBY trial for SCD and provide a clinical update by year-end.
Remains on track to dose 20 total patients in the EDIT-301 RUBY trial for SCD by year-end and provide a clinical update by year-end.
Commenced parallel patient dosing in the EDIT-301 EDITHAL trial for TDT and on track to provide a clinical update by year-end.
Presented positive initial clinical safety and efficacy data from the RUBY trial at the European Hematology Association (EHA) Hybrid Congress in June.
Erick Lucera and Linda C. Burkly were appointed as Chief Financial Officer and Chief Scientific Officer, respectively.
Revenue by Segment
Forward Guidance
Editas Medicine expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into the third quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...